Type III Polyglandular Autoimmune Syndrome Clinical Presentation

  • Author: KoKo Aung, MD, MPH, FACP; Chief Editor: George T Griffing, MD   more...
 
Updated: Jan 3, 2012
 

History

The hallmark of polyglandular autoimmune syndrome (PAS) III is the absence of adrenal insufficiency. In fact, PAS III is PAS II without adrenocortical involvement (see Neufeld and Blizzard's classification in Background). Once adrenocortical insufficiency develops, such patients are reclassified as having PAS II. The involvement of multiple glands may be apparent at the time of initial presentation, but, more commonly, individual glandular failure develops sequentially. No specific sequence exists by which the individual glandular failures develop.

  • The clinical symptoms of PAS III are a constellation of manifestations of endocrine gland failures that comprise the syndrome.
  • Autoimmune thyroiditis
    • Autoimmune thyroiditis is the characteristic of all subcategories of PAS III.
    • The presenting symptoms are goiter, those due to hypothyroidism, or both. Occasionally, destruction of the gland early in the process gives rise to the release of thyroid hormones, creating a transient hyperthyroid state (ie, Hashitoxicosis). When this process is complete, hypothyroidism becomes apparent.
    • Fatigue and depression are leading symptoms in many patients with autoimmune thyroiditis. Weight gain, cold intolerance, constipation, dry hair, sluggishness, somnolence, hoarseness, and menorrhagia also are major clinical symptoms.
    • Although some patients report a sensation of tightness in the neck, pain is usually not a prominent symptom. Patients may have a history of other autoimmune conditions such as inflammatory bowel disease, celiac disease, gonadal dysgenesis (Turner syndrome), and hepatitis C.
  • Immune-mediated diabetes
    • Classic symptoms of IMD are polyuria, polydipsia, and polyphagia. Polyuria is secondary to osmotic diuresis caused by hyperglycemia. Polydipsia is secondary to hyperosmolality. Polyphagia is probably secondary to deficient glucose utilization in the cells of the hypothalamic ventromedial nuclei.
    • Weight loss despite polyphagia is characteristic.
    • Blurred vision is common and also is secondary to hyperosmolality.
    • Paresthesia in the extremities may be present at presentation, although it is usually reversible with better glycemic control. Paresthesia is thought to be secondary to transient impairment of peripheral sensory nerve function caused by hyperglycemia.
    • Rapid development of insulin deficiency, usually precipitated by infection or other forms of stress, could result in diabetic ketoacidosis (DKA) as the initial presentation of type 1 diabetes mellitus. Abdominal pain, nausea, and vomiting are common in DKA, along with above symptoms. Altered mental status and rapid breathing are symptoms associated with severe DKA.
  • Pernicious anemia
    • Usual presenting features include insidious onset of fatigue, weakness, lightheadedness, headache, vertigo, tinnitus, and palpitations secondary to anemia.
    • Vague gastrointestinal symptoms, such as anorexia or diarrhea, may be present. Sore tongue, numbness and tingling in the extremities, and difficulty with balancing may be present at onset or may develop later in the course.
    • Neuropsychiatric manifestations may not parallel symptoms of anemia. In addition to the above neurological symptoms, irritability, memory loss, depression, hallucinations, agitation, suicidal ideation, and sphincter disturbances are recognized manifestations.
  • Vitiligo
    • Vitiligo is associated with many autoimmune endocrinopathies. Patients with an early age of onset are less likely to have PAS II or other endocrinopathies.
    • Loss of skin pigmentation in vitiligo has been linked to autoimmune destruction of melanocytes by antityrosinase and antimelanocyte antibodies. The leading symptom is loss of skin pigmentation, which is more noticeable around the mouth, eyes, nose, nipples, umbilicus, or anus. Trauma to the skin results in further loss of pigmentation (Koebner phenomenon).
  • Alopecia
    • Autoimmune alopecia (alopecia areata) ranges in severity from (1) small round patches of hair loss that regrow spontaneously to (2) persistent extensive patchy involvement to (3) the loss of all scalp hair (alopecia totalis) or all scalp and body hair including eyelashes, eyebrows, underarm hair, and pubic hair (alopecia universalis).
    • In the latter, absence of eyebrows results in perspiration trickling into the eyes; absence of eyelashes results in little protection from dust and glare. Absence of nasal hairs results in lack of protection in the nostrils or sinuses from foreign particles in the air. Spontaneous remission and recurrence are common.
Next

Physical

  • Autoimmune thyroiditis
    • Physical findings in autoimmune thyroiditis are goiter, hypothyroidism, or both. The thyroid gland is palpably enlarged in classic goitrous autoimmune thyroiditis (Hashimoto disease). The entire thyroid gland is diffusely enlarged and is firm. The surface of the thyroid gland often is bosselated, that is, characterized by numerous bosses or rounded protuberances.
    • Extrathyroidal signs of autoimmune thyroiditis and hypothyroidism include facial pallor; bradycardia; hypertension; delayed relaxation of deep-tendon reflexes; and nonpitting edema (myxedema) of the skin of the hands, feet, and eyelids.
  • Immune-mediated diabetes
    • Dry skin and mucous membranes may be observed secondary to fluid loss associated with osmotic diuresis.
    • Severe dehydration or severe DKA may lead to hypotension.
  • Pernicious anemia
    • The most striking physical sign of PA is pallor.
    • Mild scleral icterus may be present secondary to indirect hyperbilirubinemia caused by intramedullary hemolysis.
    • The tongue usually is smooth, raw, and beefy.
    • Systolic flow murmur and tachycardia may be present secondary to anemia.
    • Neurological signs may vary from diminished vibration and joint position sense to gross motor, sensory, and cognitive deficits.
    • A marked discordance may be present between the severity of neurological signs and the degree of anemia (see History).
  • Vitiligo
    • Vitiligo is characterized by symmetric areas of complete pigment loss, particularly affecting the periorificial areas and bony prominences.
    • The hairs within the patches of vitiligo often remain pigmented. However, in older lesions, the hairs also become white. Wood-lamp examination reveals more apparent chalky-white areas.
  • Alopecia
    • Alopecia areata causes different patterns of hair loss.
    • These include a localized patch of hair loss, a netlike pattern of hair loss, a serpentine pattern of hair loss that covers the periphery of the scalp similar to a serpent forming a turban over the edges of the scalp, and a diffuse form that affects the whole scalp without distinct patches.
Previous
Next

Causes

See Pathophysiology.

Previous
 
 
Contributor Information and Disclosures
Author

KoKo Aung, MD, MPH, FACP  Associate Professor, Department of Medicine, University of Texas Health Science Center at San Antonio; Adjunct Associate Professor of Public Health, University of Texas School of Public Health

KoKo Aung, MD, MPH, FACP is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Arthur B Chausmer, MD, PhD, FACP, FACE, FACN, CNS  Professor of Medicine (Endocrinology, Adj), Johns Hopkins School of Medicine; Affiliate Research Professor, Bioinformatics and Computational Biology Program, School of Computational Sciences, George Mason University; Principal, C/A Informatics, LLC

Arthur B Chausmer, MD, PhD, FACP, FACE, FACN, CNS is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Endocrinology, American College of Nutrition, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Informatics Association, American Society for Bone and Mineral Research, Endocrine Society, and International Society for Clinical Densitometry

Disclosure: Nothing to disclose.

Mark Cooper, MBBS, PhD, FRACP  Head, Diabetes & Metabolism Division, Baker Heart Research Institute, Professor of Medicine, Monash University

Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD  Professor of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physician Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical Research, Endocrine Society, International Society for Clinical Densitometry, and Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Additional Contributors

The editors wish to thank Magdi Salmon, MD, for his previous contributions to this article.

References
  1. Kahaly GJ. Polyglandular autoimmune syndromes. Eur J Endocrinol. Jul 2009;161(1):11-20. [Medline]. [Full Text].

  2. Neufeld M, Blizzard RM. Polyglandular autoimmune disease. In: Pinchera A, Doniach D, Fenzi DF, Baschieri L, eds. Autoimmune aspects of endocrine disorders. London, UK: Academic Press; 1980:357-65.

  3. Bahceci M, Tuzcu A, Pasa S, Ayyildiz O, Tuzcu S. Polyglandular autoimmune syndrome type III accompanied by common variable immunodeficiency. Gynecol Endocrinol. Jul 2004;19(1):47-50. [Medline].

  4. Ugur-Altun B, Arikan E, Guldiken S, Kara M, Tugrul A. Autoimmune polyglandular syndrome type III in monozygotic twins: a case report. Acta Clin Belg. Jul-Aug 2004;59(4):225-8. [Medline].

  5. Shimomura H, Nakase Y, Furuta H, Nishi M, Nakao T, Hanabusa T, et al. A rare case of autoimmune polyglandular syndrome type 3. Diabetes Res Clin Pract. Aug 2003;61(2):103-8. [Medline].

  6. Oki K, Yamane K, Koide J, Mandai K, Nakanishi S, Fujikawa R, et al. A case of polyglandular autoimmune syndrome type III complicated with autoimmune hepatitis. Endocr J. Oct 2006;53(5):705-9. [Medline].

  7. Noriko O, Junko T, Yuko Y, Toshiaki K, Masteru N, Tooru Y, et al. Autoimmune Polyglandular Syndrome Type III Associated with Slowly Progressive Type 1 Diabetes Mellitus, Chronic Thyroiditis, Pernicious Anemia and Idiopathic Thrombocytopenic Purpura: A Case Report. Journal of the Japan Diabetic Society. 2006;49:723-729. [Full Text].

  8. Lubinska M, Swiatkowska-Stodulska R, Kazimierska E, Sworczak K. Acquired von Willebrand's syndrome in a patient with severe primary hypothyroidism associated with myasthenia gravis in the course of autoimmune polyglandular syndrome type 3. Haemophilia. Sep 2007;13(5):675-6. [Medline]. [Full Text].

  9. Turkoglu Z, Kavala M, Kolcak O, Zindanci I, Can B. Autoimmune polyglandular syndrome-3C in a child. Dermatol Online J. Mar 15 2010;16(3):8. [Medline].

  10. Quintos JB, Grover M, Boney CM, Salas M. Autoimmune polyglandular syndrome Type 3 and growth hormone deficiency. Pediatr Diabetes. Sep 2010;11(6):438-42. [Medline].

  11. Farkas K, Nagy F, Kovács L, Csajbók E, Kovács G, Wittmann T, et al. Ulcerative colitis and primary sclerosing cholangitis as part of autoimmune polyglandular syndrome type III. Inflamm Bowel Dis. Jan 2010;16(1):10-1. [Medline].

  12. Krol TC. Myasthenia gravis, pernicious anemia, and Hashimoto's thyroiditis. Arch Neurol. Sep 1979;36(9):594-5. [Medline].

  13. Briscoe NK, Mezei MM. Polyglandular autoimmune syndrome type 3 in a patient with ocular myasthenia gravis. Muscle Nerve. Dec 2009;40(6):1064-5. [Medline].

  14. Sternthal E, Like AA, Sarantis K, Braverman LE. Lymphocytic thyroiditis and diabetes in the BB/W rat. A new model of autoimmune endocrinopathy. Diabetes. Dec 1981;30(12):1058-61. [Medline].

  15. Villano MJ, Huber AK, Greenberg DA, et al. Autoimmune thyroiditis and diabetes: dissecting the joint genetic susceptibility in a large cohort of multiplex families. J Clin Endocrinol Metab. Apr 2009;94(4):1458-66. [Medline].

  16. Huber A, Menconi F, Corathers S, et al. Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. Endocr Rev. Oct 2008;29(6):697-725. [Medline]. [Full Text].

  17. Fourati H, Mahfoudh N, Abida O, Kammoun A, Mnif F, Haddouk S, et al. HLA-DRB1/DQB1 susceptibility for autoimmune polyglandular syndrome type II and III in south of Tunisia. Ann Endocrinol (Paris). Jun 2011;72(3):232-8. [Medline].

  18. Dittmar M, Kahaly GJ. Genetics of the autoimmune polyglandular syndrome type 3 variant. Thyroid. Jul 2010;20(7):737-43. [Medline].

  19. Hunger-Battefeld W, Fath K, Mandecka A, et al. [Prevalence of polyglandular autoimmune syndrome in patients with diabetes mellitus type 1]. Med Klin (Munich). Mar 15 2009;104(3):183-91. [Medline].

  20. Baker JR Jr. Autoimmune endocrine disease. JAMA. Dec 10 1997;278(22):1931-7. [Medline].

  21. Chen Q, Kukreja A, Maclaren NK. The Autoimmune polyglandular syndromes. In: DeGroot LJ, Jameson JL. Endocrinology. Vol 1. 4th ed. Philadelphia, Pa: WB Saunders; 2001:587-99.

  22. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med. Aug 2 2001;345(5):340-50. [Medline].

  23. Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med. Jul 11 1996;335(2):99-107. [Medline].

  24. Eisenbarth GS, Wilson PW, Ward F, Buckley C, Lebovita H. The polyglandular failure syndrome: disease inheritance, HLA type, and immune function. Ann Intern Med. Oct 1979;91(4):528-33. [Medline].

  25. Kukreja A, Maclaren NK. Autoimmunity and diabetes. J Clin Endocrinol Metab. Dec 1999;84(12):4371-8. [Medline].

  26. Leibowitz G, Amir G, Losses IS, Eliakim R. Autoimmune polyglandular failure associated with malabsorption and gastric carcinoid tumour. J Intern Med. Dec 1993;234(6):625-9. [Medline].

  27. Leshin M. Polyglandular autoimmune syndromes. Am J Med Sci. Aug 1985;290(2):77-88. [Medline].

  28. Obermayer-Straub P, Manns MP. Autoimmune polyglandular syndromes. Baillieres Clin Gastroenterol. Jun 1998;12(2):293-315. [Medline].

  29. Price VH. Treatment of hair loss. N Engl J Med. Sep 23 1999;341(13):964-73. [Medline].

  30. Rodriguez Quiroz F, Berron Perez R, Ortega Martell JA, Onuma Takane E. [Type III polyglandular autoimmune syndrome. Report of a case]. Allergol Immunopathol (Madr). Sep-Oct 1995;23(5):251-3. [Medline].

  31. Sale MM, Akamizu T, Howard TD. Association of autoimmune thyroid disease with a microsatellite marker for the thyrotropin receptor gene and CTLA-4 in a Japanese population. Proc Assoc Am Physicians. Sep 1997;109(5):453-61. [Medline].

  32. Sasso FC, Carbonara O, Di Micco P, Coppola L, Torella R, Niglio A. A case of autoimmune polyglandular syndrome developed after interferon-alpha therapy. Br J Clin Pharmacol. Aug 2003;56(2):238-9. [Medline].

  33. Shaffrali F, Gawkrodger D. Management of vitiligo. Clin Exp Dermatol. Nov 2000;25(8):575-9. [Medline].

  34. Shapiro J. Alopecia Areata: Clinical Features and Treatment Options in the 90's. Presented at the International NAAF Conference, Seattle, Washington. Saturday, July 6, 1996;[Full Text].

  35. Trence DL, Morley JE, Handwerger BS. Polyglandular autoimmune syndromes. Am J Med. Jul 1984;77(1):107-16. [Medline].

  36. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab. Jan 1995;80(1):41-5. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.